Skip to main content

Table 2 Correlation of ALK IHC with clinicopathologic parameters in breast cancer

From: ALK alteration is a frequent event in aggressive breast cancers

  Total ALK present ALK absent P value
  N % N % N %
Total number of cases 972   350 36.0 622 64.0  
Age groups        
 <50 663 68.2 250 37.7 413 62.3 0.1044
 ≥50 309 31.8 100 32.4 209 67.6  
Lymph nodes        
 N0 300 32.9 108 36.0 192 64.0 0.5832
 N1 294 32.3 105 35.7 189 64.3  
 N2 192 21.1 69 35.9 123 64.1  
 N3 125 13.7 53 42.4 72 57.6  
Metastasis        
 M0 785 90.1 292 37.2 493 62.8 0.8336
 M1 86 9.9 31 36.0 55 64.0  
Tumor stage        
 I 75 8.9 20 26.7 55 73.3 0.0829
 II 372 44.1 135 36.3 237 63.7  
 III 311 36.8 130 41.8 181 58.2  
 IV 86 10.2 31 36.0 55 64.0  
Histologic grade        
 Well differentiated 74 7.7 21 28.4 53 71.6 0.0039
 Moderately differentiated 493 51.2 159 32.2 334 67.8  
 Poorly differentiated 395 41.1 156 42.0 229 58.0  
Histology        
 Infiltrating ductal carcinoma 890 94.4 329 37.0 561 63.0 0.0076
 Infiltrating lobular 40 4.2 7 17.5 33 82.5  
 Mucinous 13 1.4 2 15.4 11 84.6  
Recurrence        
 Yes 256 29.8 104 40.6 152 59.4 0.1225
 No 602 70.2 211 35.1 391 64.9  
ER        
 Negative 333 34.3 150 45.1 183 54.9 <0.0001
 Positive 638 65.7 200 31.3 438 68.7  
PR        
 Negative 412 42.5 178 43.2 234 56.8 0.0001
 Positive 558 57.5 172 30.8 386 69.2  
Triple-negative        
 Yes 147 15.2 69 46.9 78 53.1 0.0034
 No 822 84.8 281 34.2 541 65.8  
HER2 FISH        
 Amplified 275 29.0 108 39.3 167 60.7 0.2647
 Normal/gain 672 71.0 238 35.4 434 64.6  
ALK FISH        
 Amplified 126 13.3 61 48.4 65 51.6 0.0031
 Normal/gain 821 86.7 284 34.6 537 65.4  
Ki-67 IHC        
 High 818 85.8 318 38.9 500 61.1 0.0001
 Low 135 14.2 30 22.2 105 77.8  
p-AKT        
 Positive 212 22.6 132 62.3 80 37.7 <0.0001
 Negative 725 77.4 211 29.1 514 70.9  
Molecular subtype        
 HR+Her2- 460 47.4 142 30.9 318 69.1 0.0018
 HR+Her2+ 232 23.9 83 35.8 149 64.2  
 TNBC 147 15.1 69 46.9 78 53.1  
 HR-Her2+ 132 13.6 56 42.4 76 57.6  
Survival        
 OS 5 years     77.0   82.4 0.1212
  1. ALK anaplastic lymphoma kinase, IHC immunohistochemistry, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, FISH fluorescence in situ hybridization, TNBC triple-negative breast cancer, HR hormone receptor, OS overall survival
  2. *Data was not available (NA) for some cases: Age (NA = 19), Lymph nodes (NA = 74), Metastasis (NA = 101), Stage (NA = 145), Grade (NA = 50), Histology (NA = 29), ER (NA = 1), PR (NA = 2), Triple-negative (NA = 3), HER2 FISH (NA = 25), ALK FISH (NA = 24), Ki-67 (NA = 19), and p-AKT (NA = 35)